Lilly to advance dialogue on the future of healthcare at Abu Dhabi Future Health Summit 2026

Eli Lilly and Company (Lilly Gulf) will join government leaders, policymakers, healthcare experts, researchers and innovators at the Abu Dhabi Future Health Summit 2026, taking place from 20–22 October at ADNEC Centre Abu Dhabi, as the UAE advances its ambition to build a more predictive, prevention-led and innovation-ready health ecosystem.

Held under the theme “To Sense is to Predict,” the Summit will explore how advances in science, data and technology can enable earlier identification of health risks and more proactive approaches to care.

For Lilly, achieving that ambition will require more than scientific breakthroughs alone. It will depend on policy environments that can keep pace with innovation, health systems equipped to adopt new approaches, evidence that supports informed decision-making, and stronger collaboration across government, healthcare, research and industry.

Across the Summit, Lilly will contribute to discussions spanning medical innovation, clinical research, real-world evidence, health-system readiness, public private partnerships, and sustainable access to innovation.

The conversations come as Lilly marks 150 years of scientific discovery, while looking ahead to a period in which the pace of progress in medicine is creating new opportunities to address some of the world’s most significant health challenges.

Leena Aziz, Senior Director and Head of Corporate and Government Affairs, Lilly Gulf (UAE, Kuwait and Qatar), said: “For 150 years, Lilly has been driven by the belief that science can change what is possible for patients. Today, the opportunity before us is extraordinary, but scientific progress cannot deliver its full value in isolation. We need policies that enable innovation, health systems that are ready to adopt it, and partnerships that bring together the right capabilities around shared health priorities. Abu Dhabi has demonstrated significant ambition in building an environment where those elements can come together, and we look forward to contributing to that dialogue.”

Lilly’s participation also builds on its broader engagement with healthcare stakeholders in the UAE, including across areas including the development of centres of excellence in neurodegenerative disease care, AI-enabled obesity and cardiometabolic care models tailored to the Abu Dhabi population amongst other partnerships.

As healthcare becomes more predictive, personalised and data-driven, the challenge for health systems will not only be to keep pace with discovery, but to create the conditions in which innovation can be responsibly evaluated, adopted and translated into better outcomes.

For Lilly, the objective is clear: to contribute its science, global experience and capabilities while working with partners to help build healthcare systems prepared for what comes next.